| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 27 | 2024 | 1260 | 4.290 |
Why?
|
| HIV Infections | 52 | 2024 | 5097 | 3.980 |
Why?
|
| Viral Load | 34 | 2024 | 819 | 3.970 |
Why?
|
| Drug Resistance, Viral | 12 | 2023 | 278 | 1.720 |
Why?
|
| RNA, Viral | 12 | 2024 | 303 | 1.630 |
Why?
|
| Dried Blood Spot Testing | 4 | 2022 | 24 | 1.610 |
Why?
|
| Anti-HIV Agents | 20 | 2023 | 1324 | 1.610 |
Why?
|
| Humans | 69 | 2024 | 14537 | 1.420 |
Why?
|
| Anti-Retroviral Agents | 9 | 2024 | 551 | 1.390 |
Why?
|
| Sensitivity and Specificity | 14 | 2024 | 385 | 1.380 |
Why?
|
| Point-of-Care Testing | 3 | 2020 | 71 | 1.310 |
Why?
|
| Specimen Handling | 4 | 2021 | 105 | 0.980 |
Why?
|
| South Africa | 33 | 2024 | 7596 | 0.930 |
Why?
|
| Adult | 30 | 2024 | 5913 | 0.910 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2020 | 472 | 0.900 |
Why?
|
| Molecular Diagnostic Techniques | 5 | 2017 | 132 | 0.870 |
Why?
|
| National Health Programs | 4 | 2022 | 78 | 0.830 |
Why?
|
| Treatment Failure | 9 | 2023 | 175 | 0.800 |
Why?
|
| Blood | 4 | 2016 | 51 | 0.770 |
Why?
|
| Nucleic Acid Amplification Techniques | 2 | 2021 | 35 | 0.760 |
Why?
|
| HIV-2 | 1 | 2021 | 15 | 0.750 |
Why?
|
| Female | 28 | 2024 | 9103 | 0.750 |
Why?
|
| Plasma | 3 | 2023 | 39 | 0.740 |
Why?
|
| Primary Health Care | 2 | 2024 | 240 | 0.720 |
Why?
|
| Virus Replication | 5 | 2009 | 88 | 0.690 |
Why?
|
| HIV Protease Inhibitors | 2 | 2020 | 92 | 0.680 |
Why?
|
| Male | 23 | 2024 | 6754 | 0.680 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2017 | 59 | 0.680 |
Why?
|
| Hepatitis B virus | 6 | 2009 | 157 | 0.660 |
Why?
|
| Treatment Adherence and Compliance | 2 | 2019 | 9 | 0.650 |
Why?
|
| Early Diagnosis | 5 | 2021 | 82 | 0.640 |
Why?
|
| Drug Monitoring | 2 | 2017 | 55 | 0.640 |
Why?
|
| CD4 Lymphocyte Count | 9 | 2022 | 656 | 0.630 |
Why?
|
| Patient Transfer | 1 | 2018 | 6 | 0.610 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 529 | 0.610 |
Why?
|
| Middle Aged | 15 | 2024 | 3601 | 0.580 |
Why?
|
| Adolescent | 13 | 2023 | 2985 | 0.540 |
Why?
|
| Labyrinthitis | 1 | 2016 | 1 | 0.540 |
Why?
|
| Migraine Disorders | 1 | 2016 | 1 | 0.540 |
Why?
|
| Otitis Media with Effusion | 1 | 2016 | 1 | 0.540 |
Why?
|
| Sensation Disorders | 1 | 2016 | 1 | 0.540 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 1 | 0.540 |
Why?
|
| Benign Paroxysmal Positional Vertigo | 1 | 2016 | 1 | 0.540 |
Why?
|
| Postural Balance | 1 | 2016 | 2 | 0.530 |
Why?
|
| Cost of Illness | 1 | 2018 | 167 | 0.530 |
Why?
|
| Ataxia | 1 | 2016 | 4 | 0.530 |
Why?
|
| Vestibular Diseases | 2 | 2016 | 2 | 0.520 |
Why?
|
| RNA, Small Interfering | 4 | 2009 | 49 | 0.520 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 1422 | 0.510 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 90 | 0.510 |
Why?
|
| Young Adult | 13 | 2021 | 2498 | 0.510 |
Why?
|
| Child | 9 | 2024 | 2242 | 0.490 |
Why?
|
| Cohort Studies | 8 | 2021 | 967 | 0.490 |
Why?
|
| Polymerase Chain Reaction | 6 | 2020 | 260 | 0.480 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 1 | 0.460 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2014 | 1 | 0.460 |
Why?
|
| Mutation Rate | 1 | 2014 | 7 | 0.460 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 8 | 0.460 |
Why?
|
| Infant, Newborn | 7 | 2020 | 1479 | 0.430 |
Why?
|
| Infant | 10 | 2019 | 2244 | 0.410 |
Why?
|
| Reverse Transcriptase Inhibitors | 6 | 2020 | 118 | 0.410 |
Why?
|
| Genotype | 8 | 2017 | 442 | 0.400 |
Why?
|
| Population Surveillance | 3 | 2021 | 325 | 0.400 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2019 | 472 | 0.390 |
Why?
|
| Vestibule, Labyrinth | 1 | 2011 | 1 | 0.380 |
Why?
|
| Electric Stimulation Therapy | 1 | 2011 | 2 | 0.380 |
Why?
|
| HIV | 5 | 2020 | 380 | 0.380 |
Why?
|
| Aged | 7 | 2021 | 1740 | 0.370 |
Why?
|
| Depression | 2 | 2024 | 121 | 0.350 |
Why?
|
| RNA Interference | 4 | 2007 | 45 | 0.340 |
Why?
|
| Mutation | 6 | 2017 | 306 | 0.340 |
Why?
|
| Prospective Studies | 5 | 2020 | 1160 | 0.330 |
Why?
|
| Trans-Activators | 3 | 2005 | 23 | 0.330 |
Why?
|
| Nanoparticles | 2 | 2009 | 104 | 0.320 |
Why?
|
| Polyethylene Glycols | 1 | 2009 | 49 | 0.320 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 181 | 0.310 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2021 | 56 | 0.310 |
Why?
|
| Pregnancy | 6 | 2020 | 1862 | 0.310 |
Why?
|
| Treatment Outcome | 5 | 2021 | 889 | 0.300 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 217 | 0.290 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 468 | 0.280 |
Why?
|
| DNA | 3 | 2009 | 73 | 0.270 |
Why?
|
| Genotyping Techniques | 2 | 2016 | 38 | 0.260 |
Why?
|
| RNA, Antisense | 1 | 2005 | 3 | 0.260 |
Why?
|
| Prevalence | 6 | 2023 | 1192 | 0.240 |
Why?
|
| Edetic Acid | 1 | 2024 | 8 | 0.230 |
Why?
|
| Guideline Adherence | 2 | 2020 | 43 | 0.220 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2023 | 3 | 0.220 |
Why?
|
| Point-of-Care Systems | 3 | 2023 | 91 | 0.210 |
Why?
|
| RNA | 1 | 2022 | 26 | 0.210 |
Why?
|
| Risk Factors | 4 | 2023 | 1475 | 0.210 |
Why?
|
| Epidemics | 1 | 2023 | 65 | 0.200 |
Why?
|
| Biological Assay | 1 | 2021 | 32 | 0.190 |
Why?
|
| Retrospective Studies | 4 | 2020 | 799 | 0.190 |
Why?
|
| Mutation, Missense | 3 | 2016 | 65 | 0.190 |
Why?
|
| Age Factors | 3 | 2021 | 370 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 139 | 0.180 |
Why?
|
| Gene Expression | 2 | 2014 | 43 | 0.180 |
Why?
|
| Health Facilities | 1 | 2021 | 40 | 0.180 |
Why?
|
| Mice | 4 | 2009 | 135 | 0.180 |
Why?
|
| Animals | 5 | 2009 | 1081 | 0.170 |
Why?
|
| Drug Substitution | 1 | 2020 | 33 | 0.170 |
Why?
|
| Africa South of the Sahara | 5 | 2021 | 353 | 0.170 |
Why?
|
| Viremia | 1 | 2020 | 66 | 0.170 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 2 | 2016 | 29 | 0.160 |
Why?
|
| Paper | 1 | 2019 | 2 | 0.160 |
Why?
|
| Smartphone | 1 | 2019 | 4 | 0.160 |
Why?
|
| Filtration | 1 | 2019 | 3 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2019 | 14 | 0.160 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 13 | 0.160 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 14 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 150 | 0.160 |
Why?
|
| Global Health | 2 | 2017 | 193 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 34 | 0.160 |
Why?
|
| Temperature | 1 | 2019 | 56 | 0.160 |
Why?
|
| Tenofovir | 2 | 2017 | 171 | 0.160 |
Why?
|
| Hypertension | 1 | 2023 | 419 | 0.150 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2018 | 3 | 0.150 |
Why?
|
| Mothers | 1 | 2020 | 195 | 0.150 |
Why?
|
| Lopinavir | 4 | 2020 | 137 | 0.150 |
Why?
|
| Ritonavir | 4 | 2020 | 137 | 0.150 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2021 | 226 | 0.150 |
Why?
|
| Plasmids | 2 | 2009 | 23 | 0.150 |
Why?
|
| Acanthocytes | 1 | 2017 | 2 | 0.150 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2017 | 12 | 0.150 |
Why?
|
| Chorea | 1 | 2017 | 13 | 0.150 |
Why?
|
| Laboratories | 1 | 2018 | 47 | 0.150 |
Why?
|
| Hospitals, University | 1 | 2017 | 16 | 0.150 |
Why?
|
| Huntington Disease | 1 | 2017 | 22 | 0.140 |
Why?
|
| Antibodies | 1 | 1997 | 25 | 0.140 |
Why?
|
| Dementia | 1 | 2017 | 22 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 71 | 0.140 |
Why?
|
| Cognition Disorders | 1 | 2017 | 36 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.140 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2021 | 329 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 33 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2019 | 1748 | 0.140 |
Why?
|
| Gene Products, pol | 1 | 2016 | 5 | 0.140 |
Why?
|
| Automation, Laboratory | 1 | 2017 | 13 | 0.140 |
Why?
|
| Community Health Services | 1 | 2017 | 58 | 0.140 |
Why?
|
| Lost to Follow-Up | 1 | 2017 | 62 | 0.140 |
Why?
|
| Postpartum Period | 1 | 2017 | 85 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 74 | 0.130 |
Why?
|
| Reflex, Vestibulo-Ocular | 1 | 2016 | 1 | 0.130 |
Why?
|
| Vertigo | 1 | 2016 | 1 | 0.130 |
Why?
|
| Vestibular Function Tests | 1 | 2016 | 1 | 0.130 |
Why?
|
| Head Impulse Test | 1 | 2016 | 1 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 77 | 0.130 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2017 | 73 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 125 | 0.130 |
Why?
|
| Algorithms | 2 | 2017 | 106 | 0.130 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2014 | 6 | 0.120 |
Why?
|
| Mass Screening | 1 | 2016 | 245 | 0.120 |
Why?
|
| Cell Line | 4 | 2009 | 93 | 0.120 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 43 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 280 | 0.120 |
Why?
|
| Didanosine | 1 | 2014 | 11 | 0.120 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2014 | 16 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 22 | 0.110 |
Why?
|
| Parvoviridae Infections | 1 | 2014 | 4 | 0.110 |
Why?
|
| Parvovirus B19, Human | 1 | 2014 | 5 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 18 | 0.110 |
Why?
|
| Viral Tropism | 1 | 2013 | 9 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 62 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2014 | 149 | 0.110 |
Why?
|
| Viral Regulatory and Accessory Proteins | 3 | 2005 | 27 | 0.110 |
Why?
|
| Prognosis | 1 | 2014 | 199 | 0.110 |
Why?
|
| Time Factors | 3 | 2020 | 507 | 0.110 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 1 | 0.100 |
Why?
|
| Multigene Family | 1 | 2012 | 6 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 8 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 41 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 11 | 0.100 |
Why?
|
| Liposomes | 2 | 2009 | 33 | 0.100 |
Why?
|
| Molecular Sequence Data | 4 | 2015 | 263 | 0.100 |
Why?
|
| Fetal Diseases | 1 | 2012 | 7 | 0.100 |
Why?
|
| Virology | 1 | 2012 | 13 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 56 | 0.100 |
Why?
|
| Electric Stimulation | 1 | 2011 | 7 | 0.100 |
Why?
|
| Electrodes | 1 | 2011 | 7 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2010 | 11 | 0.090 |
Why?
|
| Counseling | 2 | 2024 | 143 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2009 | 13 | 0.090 |
Why?
|
| Dipeptides | 1 | 2009 | 2 | 0.090 |
Why?
|
| Transfection | 1 | 2009 | 29 | 0.080 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2021 | 198 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 11 | 0.080 |
Why?
|
| Molecular Structure | 1 | 2009 | 32 | 0.080 |
Why?
|
| Genetic Vectors | 2 | 2006 | 55 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 279 | 0.070 |
Why?
|
| Genes, gag | 1 | 2006 | 6 | 0.070 |
Why?
|
| World Health Organization | 2 | 2017 | 137 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2006 | 20 | 0.070 |
Why?
|
| Dideoxynucleosides | 2 | 2017 | 29 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2005 | 39 | 0.060 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2005 | 12 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 563 | 0.060 |
Why?
|
| DNA, Viral | 2 | 2010 | 165 | 0.060 |
Why?
|
| Hepatitis B, Chronic | 1 | 2005 | 45 | 0.060 |
Why?
|
| Comorbidity | 1 | 2024 | 188 | 0.060 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2023 | 4 | 0.050 |
Why?
|
| Genomics | 1 | 2023 | 109 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 21 | 0.050 |
Why?
|
| Reference Standards | 1 | 2021 | 29 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2023 | 317 | 0.050 |
Why?
|
| Base Sequence | 2 | 2014 | 149 | 0.050 |
Why?
|
| Carrier State | 1 | 2021 | 92 | 0.040 |
Why?
|
| Namibia | 1 | 2020 | 19 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2021 | 151 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.040 |
Why?
|
| Isoniazid | 1 | 2021 | 110 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 42 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 18 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 22 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 163 | 0.040 |
Why?
|
| Zambia | 1 | 2020 | 115 | 0.040 |
Why?
|
| Adolescent Health | 1 | 2019 | 15 | 0.040 |
Why?
|
| Government Programs | 1 | 2019 | 30 | 0.040 |
Why?
|
| Rifampin | 1 | 2021 | 197 | 0.040 |
Why?
|
| Delivery, Obstetric | 1 | 2020 | 79 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 80 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 107 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 1 | 1999 | 2 | 0.040 |
Why?
|
| Mobile Applications | 1 | 2019 | 12 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 227 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 64 | 0.040 |
Why?
|
| DNA Primers | 1 | 1999 | 55 | 0.040 |
Why?
|
| Zimbabwe | 1 | 2019 | 120 | 0.040 |
Why?
|
| Sample Size | 1 | 2018 | 4 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 22 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 151 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 22 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 239 | 0.040 |
Why?
|
| Intersectoral Collaboration | 1 | 2018 | 7 | 0.040 |
Why?
|
| Abetalipoproteinemia | 1 | 2017 | 2 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2017 | 15 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2018 | 57 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 1997 | 8 | 0.040 |
Why?
|
| Mozambique | 1 | 2017 | 55 | 0.040 |
Why?
|
| Rabbits | 1 | 1997 | 35 | 0.040 |
Why?
|
| Glutathione Transferase | 1 | 1997 | 20 | 0.040 |
Why?
|
| Nelfinavir | 1 | 2017 | 6 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2017 | 67 | 0.040 |
Why?
|
| Data Collection | 1 | 2018 | 86 | 0.040 |
Why?
|
| Immunization | 1 | 1997 | 63 | 0.040 |
Why?
|
| United Nations | 1 | 2017 | 12 | 0.040 |
Why?
|
| Zidovudine | 1 | 2017 | 59 | 0.040 |
Why?
|
| Uganda | 1 | 2017 | 197 | 0.040 |
Why?
|
| DNA Damage | 1 | 1997 | 12 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 23 | 0.040 |
Why?
|
| Alkynes | 1 | 2017 | 117 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2017 | 123 | 0.030 |
Why?
|
| Lamivudine | 1 | 2017 | 89 | 0.030 |
Why?
|
| Neonatal Screening | 1 | 2017 | 24 | 0.030 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2017 | 41 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2017 | 26 | 0.030 |
Why?
|
| Medical Audit | 1 | 2017 | 26 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2016 | 11 | 0.030 |
Why?
|
| Piperazines | 1 | 2017 | 82 | 0.030 |
Why?
|
| Oxazines | 1 | 2017 | 81 | 0.030 |
Why?
|
| Benzoxazines | 1 | 2017 | 123 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 85 | 0.030 |
Why?
|
| Liver | 1 | 1997 | 74 | 0.030 |
Why?
|
| Pyridones | 1 | 2017 | 100 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 101 | 0.030 |
Why?
|
| Darunavir | 1 | 2015 | 12 | 0.030 |
Why?
|
| Atazanavir Sulfate | 1 | 2015 | 10 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 2015 | 23 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 685 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2015 | 45 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 38 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 91 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 265 | 0.030 |
Why?
|
| Receptors, HIV | 1 | 2013 | 12 | 0.030 |
Why?
|
| Stavudine | 1 | 2014 | 78 | 0.030 |
Why?
|
| Cations | 1 | 2009 | 7 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 48 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2010 | 284 | 0.020 |
Why?
|
| Interferons | 1 | 2007 | 9 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2006 | 3 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2006 | 9 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 12 | 0.020 |
Why?
|
| Biomarkers | 1 | 2007 | 327 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 1997 | 4 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 7 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1997 | 79 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 73 | 0.010 |
Why?
|